Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Potential Blockbuster' Dupixent Set For EU Eczema OK

Executive Summary

While Dupixent looks set for use in Europe for treating moderate-to-severe atopic dermatitis, analysts believe the biologic has a great future in other indications and could eventually become a blockbuster.

You may also be interested in...



Galderma Cuts Topical Derma R&D In Favor Of Systemic Treatments

Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.

Regeneron And Sanofi Antibody Discovery Deal To End

Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.

Sanofi 2Q: Dupixent's First Set Of Sales Are On Track

No surprises from Sanofi in the second quarter as sales of its flagship diabetes drug continue to fall – but a strong performance from recently launched Dupixent provided the French pharma with a refreshing reprieve in its earnings update.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel